IPP Bureau
.jpg "IPM registers 6 % yoy revenue growth in Nov 2021.")
IPM registers 6 % yoy revenue growth in Nov 2021.
By IPP Bureau - December 08, 2021
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Dr. Srivari Chandrashekhar appointed secretary of Department of Science and Technology
By IPP Bureau - December 07, 2021
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
RDIF offers vaccine for adolescents aged 12-17 in India
By IPP Bureau - December 07, 2021
Sputnik M is a new member of the Sputnik vaccines family
Oncologists call for adoption of tech innovations to treat cancer
By IPP Bureau - December 07, 2021
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Biocon partners with Tabuk Pharmaceuticals as it expands in the Middle East
By IPP Bureau - December 07, 2021
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Gan & Lee gets U.S. FDA clearance for novel glucagon-like peptide-1 analogue
By IPP Bureau - December 07, 2021
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects
Fujifilm collaborates with DCC Animal hospital for diagnostics support
By IPP Bureau - December 07, 2021
Fujifilm India will be providing healthcare Imaging devices and equipment’s to increase the standards of the veterinary care in India.
Hilleman Laboratories invests US $ 58 mn to establish vaccine hub in Singapore
By IPP Bureau - December 07, 2021
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Wipro-GE unveils B2B e-commerce platform for medical equipment
By IPP Bureau - December 07, 2021
It is an extension of GE Healthcare’s online service delivery enterprise Service Shop
Study shows Glaxo-Vir drug works against Omicron mutations
By IPP Bureau - December 07, 2021
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Early management of Covid-19 key to reduce mortality and hospitalisation
By IPP Bureau - December 06, 2021
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
AWS partners with Pfizer to accelerate drug development
By IPP Bureau - December 06, 2021
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Roche develops tests to identify Omicron variant
By IPP Bureau - December 06, 2021
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
Lilly's bamlanivimab with etesevimab authorized for emergency use in Covid-19 patients under 12
By IPP Bureau - December 06, 2021
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Roche to launch SARS-CoV-2 and flu A/B Rapid Antigen Test in countries accepting the CE mark
By IPP Bureau - December 06, 2021
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
